|
1
|
Dziurzynski K, Chang SM, Heimberger AB,
Kalejta RF, McGregor Dallas SR, Smit M, Soroceanu L, Cobbs CS; HCMV
and Gliomas Symposium: Consensus on the role of human
cytomegalovirus in glioblastoma. Neuro Oncol. 14:246–255. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cunningham C, Gatherer D, Hilfrich B,
Baluchova K, Dargan DJ, Thomson M, Griffiths PD, Wilkinson GW,
Schulz TF and Davison AJ: Sequences of complete human
cytomegalovirus genomes from infected cell cultures and clinical
specimens. J Gen Virol. 91:605–615. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dunn W, Chou C, Li H, Hai R, Patterson D,
Stolc V, Zhu H and Liu F: Functional profiling of a human
cytomegalovirus genome. Proc Natl Acad Sci USA. 100:14223–14228.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Slobedman B and Mocarski ES: Quantitative
analysis of latent human cytomegalovirus. J Virol. 73:4806–4812.
1999.PubMed/NCBI
|
|
5
|
Bego MG, Keyes LR, Maciejewski J and St
Jeor SC: Human cytomegalovirus latency-associated protein LUNA is
expressed during HCMV infections in vivo. Arch Virol.
156:1847–1851. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wills MR, Poole E, Lau B, Krishna B and
Sinclair JH: The immunology of human cytomegalovirus latency: Could
latent infection be cleared by novel immunotherapeutic strategies?
Cell Mol Immunol. 12:128–138. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Goodrum F: Human cytomegalovirus latency:
Approaching the gordian knot. Annu Rev Virol. 3:333–357. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Soderberg-Naucler C, Fish KN and Nelson
JA: Reactivation of latent human cytomegalovirus by allogeneic
stimulation of blood cells from healthy donors. Cell. 91:119–126.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu XF, Wang X, Yan S, Zhang Z, Abecassis
M and Hummel M: Epigenetic control of cytomegalovirus latency and
reactivation. Viruses. 5:1325–1345. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sinclair J: Human cytomegalovirus: Latency
and reactivation in the myeloid lineage. J Clin Virol. 41:180–185.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gan X, Wang H, Yu Y, Yi W, Zhu S, Li E and
Liang Y: Epigenetically repressing human cytomegalovirus lytic
infection and reactivation from latency in THP-1 model by targeting
H3K9 and H3K27 histone demethylases. PLoS One. 12:e01753902017.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sinclair J: Chromatin structure regulates
human cytomegalovirus gene expression during latency, reactivation
and lytic infection. Biochim Biophys Acta. 1799:286–295. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Meier JL: Reactivation of the human
cytomegalovirus major immediate-early regulatory region and viral
replication in embryonal NTera2 cells: Role of trichostatin A,
retinoic acid, and deletion of the 21-base-pair repeats and
modulator. J Virol. 75:1581–1593. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ioudinkova E, Arcangeletti MC, Rynditch A,
De Conto F, Motta F, Covan S, Pinardi F, Razin SV and Chezzi C:
Control of human cytomegalovirus gene expression by differential
histone modifications during lytic and latent infection of a
monocytic cell line. Gene. 384:120–128. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Murphy JC, Fischle W, Verdin E and
Sinclair JH: Control of cytomegalovirus lytic gene expression by
histone acetylation. EMBO J. 21:1112–1120. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Baryawno N, Rahbar A, Wolmer-Solberg N,
Taher C, Odeberg J, Darabi A, Khan Z, Sveinbjörnsson B, FuskevÅg
OM, Segerström L, et al: Detection of human cytomegalovirus in
medulloblastomas reveals a potential therapeutic target. J Clin
Invest. 121:4043–4055. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rahbar A, Orrego A, Peredo I, Dzabic M,
Wolmer-Solberg N, Strååt K, Stragliotto G and Söderberg-Nauclér C:
Human cytomegalovirus infection levels in glioblastoma multiforme
are of prognostic value for survival. J Clin Virol. 57:36–42. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wolmer-Solberg N, Baryawno N, Rahbar A,
Fuchs D, Odeberg J, Taher C, Wilhelmi V, Milosevic J, Mohammad AA,
Martinsson T, et al: Frequent detection of human cytomegalovirus in
neuroblastoma: A novel therapeutic target? Int J Cancer.
133:2351–2361. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Johnson DR, Fogh SE, Giannini C, Kaufmann
TJ, Raghunathan A, Theodosopoulos PV and Clarke JL: Case-based
review: Newly diagnosed glioblastoma. Neuro Oncol Pract. 2:106–121.
2015. View Article : Google Scholar
|
|
21
|
Alifieris C and Trafalis DT: Glioblastoma
multiforme: Pathogenesis and treatment. Pharmacol Ther. 152:63–82.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tyagi V, Theobald J, Barger J, Bustoros M,
Bayin NS, Modrek AS, Kader M, Anderer EG, Donahue B, Fatterpekar G,
et al: Traumatic brain injury and subsequent glioblastoma
development: Review of the literature and case reports. Surg Neurol
Int. 7:782016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Herbein G: The human cytomegalovirus, from
oncomodulation to oncogenesis. Viruses. 10(pii): E4082018.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Michaelis M, Baumgarten P, Mittelbronn M,
Driever PH, Doerr HW and Cinatl J Jr: Oncomodulation by human
cytomegalovirus: Novel clinical findings open new roads. Med
Microbiol Immunol. 200:1–5. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Estekizadeh A, Landazur N, Bartek J Jr,
Beltoft Brøchner C, Davoudi B, Broholm H, Karimi M, Ekström TJ and
Rahbar A: Increased cytomegalovirus replication by 5-Azacytidine
and viral-induced cytoplasmic expression of DNMT1 in
medulloblastoma and endothelial cells. Int J Oncol. 52:1317–1327.
2018.PubMed/NCBI
|
|
26
|
Di Costanzo A, Del Gaudio N, Migliaccio A
and Altucci L: Epigenetic drugs against cancer: An evolving
landscape. Arch Toxicol. 88:1651–1668. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
(Human protein Atlas: https://www.proteinatlas.org/ENSG00000130816-DNMT1/cell)Version.
18.1, Atlas updated. 2018 11 15
|
|
29
|
Khan Z, Yaiw KC, Wilhelmi V, Lam H, Rahbar
A, Stragliotto G and Söderberg-Nauclér C: Human cytomegalovirus
immediate early proteins promote degradation of connexin 43 and
disrupt gap junction communication: Implications for a role in
gliomagenesis. Carcinogenesis. 35:145–154. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Stragliotto G, Rahbar A, Solberg NW, Lilja
A, Taher C, Orrego A, Bjurman B, Tammik C, Skarman P, Peredo I, et
al: Effects of valganciclovir as an add-on therapy in patients with
cytomegalovirus-positive glioblastoma: A randomized, double-blind,
hypothesis-generating study. Int J Cancer. 133:1204–1213. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Soderberg-Naucler C, Rahbar A and
Stragliotto G: Survival in patients with glioblastoma receiving
valganciclovir. N Engl J Med. 369:985–986. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bettegowda C, Agrawal N, Jiao Y, Sausen M,
Wood LD, Hruban RH, Rodriguez FJ, Cahill DP, McLendon R, Riggins G,
et al: Mutations in CIC and FUBP1 contribute to human
oligodendroglioma. Science. 333:1453–1455. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bibikova M, Barnes B, Tsan C, Ho V,
Klotzle B, Le JM, Delano D, Zhang L, Schroth GP, Gunderson KL, et
al: High density DNA methylation array with single CpG site
resolution. Genomics. 98:288–295. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Brennan CW, Verhaak RG, McKenna A, Campos
B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ,
Berman SH, et al: The somatic genomic landscape of glioblastoma.
Cell. 155:462–477. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ahluwalia MS, Xie H, Dahiya S,
Hashemi-Sadraei N, Schiff D, Fisher PG, Chamberlain MC, Pannullo S,
Newton HB, Brewer C, et al: Efficacy and patient-reported outcomes
with dose-intense temozolomide in patients with newly diagnosed
pure and mixed anaplastic oligodendroglioma: A phase II multicenter
study. J Neurooncol. 122:111–119. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Vogelbaum MA, Hu C, Peereboom DM,
Macdonald DR, Giannini C, Suh JH, Jenkins RB, Laack NN, Brachman
DG, Shrieve DC, et al: Phase II trial of pre-irradiation and
concurrent temozolomide in patients with newly diagnosed anaplastic
oligodendrogliomas and mixed anaplastic oligoastrocytomas: Long
term results of RTOG BR0131. J Neurooncol. 124:413–420. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Aihara K, Mukasa A, Nagae G, Nomura M,
Yamamoto S, Ueda H, Tatsuno K, Shibahara J, Takahashi M, Momose T,
et al: Genetic and epigenetic stability of oligodendrogliomas at
recurrence. Acta Neuropathol Commun. 5:182017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Suvà ML: Genetics and epigenetics of
gliomas. Swiss Med Wkly. 44:w140182014.
|
|
39
|
Li X, Zhang Q, Shi Q, Liu Y, Zhao K, Shen
Q, Shi Y, Liu X, Wang C, Li N, et al: Demethylase Kdm6a
epigenetically promotes IL-6 and IFN-β production in macrophages. J
Autoimmun. 80:85–94. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Winfield J, Esbitt A, Seutter SF, Desai B,
Abdo M, Vasconez M, Laidlaw W, Green K, Shamseddin SM and Borghaei
RC: Effect of inflammatory cytokines on DNA methylation and
demethylation. FASEB J. 30 (Suppl 1):S10532016.
|
|
41
|
Cheeran MC, Hu S, Yager SL, Gekker G,
Peterson PK and Lokensgard JR: Cytomegalovirus induces cytokine and
chemokine production differentially in microglia and astrocytes:
Antiviral implications. J Neurovirol. 7:135–147. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kline JN, Hunninghake GM, He B, Monick MM
and Hunninghake GW: Synergistic activation of the human
cytomegalovirus major immediate early promoter by prostaglandin E2
and cytokines. Exp Lung Res. 24:3–14. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Gong M, Shi W, Qi J, Shao G, Shi Z, Wang
J, Chen J and Chu R: Alu hypomethylation and MGMT hypermethylation
in serum as biomarkers of glioma. Oncotarget. 8:76797–76806. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Nagarajan RP and Costello JF: Epigenetic
mechanisms in glioblastoma multiforme. Semin Cancer Biol.
19:188–197. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Cadieux B, Ching TT, VandenBerg SR and
Costello JF: Genome-wide hypomethylation in human glioblastomas
associated with specific copy number alteration,
methylenetetrahydrofolate reductase allele status, and increased
proliferation. Cancer Res. 66:8469–8476. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Costello JF, Berger MS, Huang HS and
Cavenee WK: Silencing of p16/CDKN2 expression in human
gliomas by methylation and chromatin condensation. Cancer Res.
56:2405–2410. 1996.PubMed/NCBI
|
|
47
|
Alaminos M, Davalos V, Ropero S, Setién F,
Paz MF, Herranz M, Fraga MF, Mora J, Cheung NK, Gerald WL, et al:
EMP3, a myelin-related gene located in the critical 19q13.3
region, is epigenetically silenced and exhibits features of a
candidate tumor suppressor in glioma and neuroblastoma. Cancer Res.
65:2565–2571. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Nakamura M, Watanabe T, Yonekawa Y,
Kleihues P and Ohgaki H: Promoter methylation of the DNA repair
gene MGMT in astrocytomas is frequently associated with G:C ->
A:T mutations of the TP53 tumor suppressor gene. Carcinogenesis.
22:1715–1719. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Hesson L, Bieche I, Krex D, Criniere E,
Hoang-Xuan K, Maher ER and Latif F: Frequent epigenetic
inactivation of RASSF1A and BLU genes located within
the critical 3p21.3 region in gliomas. Oncogene. 23:2408–2419.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Uhlmann K, Rohde K, Zeller C, Szymas J,
Vogel S, Marczinek K, Thiel G, Nürnberg P and Laird PW: Distinct
methylation profiles of glioma subtypes. Int J Cancer. 106:52–59.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Nakamura M, Yonekawa Y, Kleihues P and
Ohgaki H: Promoter hypermethylation of the RB1 gene in
glioblastomas. Lab Invest. 81:77–82. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Hegi ME, Diserens AC, Gorlia T, Hamou MF,
de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani
L, et al: MGMT gene silencing and benefit from temozolomide
in glioblastoma. N Engl J Med. 352:997–1003. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Gonzalez-Gomez P, Bello MJ, Arjona D,
Lomas J, Alonso ME, De Campos JM, Vaquero J, Isla A, Gutierrez M
and Rey JA: Promoter hypermethylation of multiple genes in
astrocytic gliomas. Int J Oncol. 22:601–608. 2003.PubMed/NCBI
|
|
54
|
Alonso ME, Bello MJ, Gonzalez-Gomez P,
Arjona D, Lomas J, de Campos JM, Isla A, Sarasa JL and Rey JA:
Aberrant promoter methylation of multiple genes in
oligodendrogliomas and ependymomas. Cancer Genet Cytogenet.
144:134–142. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Nawaz I, Qiu X, Wu H, Li Y, Fan Y, Hu LF,
Zhou Q and Ernberg I: Development of a multiplex methylation
specific PCR suitable for (early) detection of non-small cell lung
cancer. Epigenetics. 9:1138–1148. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Paz MF, Yaya-Tur R, Rojas-Marcos I, Reynes
G, Pollan M, Aguirre-Cruz L, García-Lopez JL, Piquer J, Safont MJ,
Balaña C, et al: CpG island hypermethylation of the DNA repair
enzyme methyltransferase predicts response to temozolomide in
primary gliomas. Clin Cancer Res. 10:4933–4938. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Caren H, Pollard SM and Beck S: The good,
the bad and the ugly: Epigenetic mechanisms in glioblastoma. Mol
Aspects Med. 34:849–862. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Flanagan S, Lee M, Li CC, Suter CM and
Buckland ME: Promoter methylation analysis of IDH genes in human
gliomas. Front Oncol. 2:1932012. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Hughes LA, Melotte V, de Schrijver J, de
Maat M, Smit VT, Bovée JV, French PJ, van den Brandt PA, Schouten
LJ, de Meyer T, et al: The CpG island methylator phenotype: What's
in a name? Cancer Res. 73:5858–5868. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Dong Y, Zhao H, Li H, Li X and Yang S: DNA
methylation as an early diagnostic marker of cancer (Review).
Biomed Rep. 2:326–330. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Fardi M, Solali S and Farshdousti Hagh M:
Epigenetic mechanisms as a new approach in cancer treatment: An
updated review. Genes Dis. 5:304–311. 2018. View Article : Google Scholar : PubMed/NCBI
|
